Commonly occurring loss and mutation of the MXII gene in prostate cancer

Genes Chromosomes and Cancer

Volumn 22, Issue 4, 1998, Pages 295-304

  Prochownik, Edward V ^a,b,c   Grove, Linette Eagle ^a   Deubler, Debra ^d   Zhu, Xiao Lin ^d   Stephenson, Robert A ^d   Rohr, L Ralph ^d   Yin, Xiaoying ^a   Brothman, Arthur R ^d  

^a CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^d UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; HELIX LOOP HELIX PROTEIN; MUTANT PROTEIN; ONCOPROTEIN;

ARTICLE; CHROMOSOME 10Q; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE LOSS; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DNA BINDING;

BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CHROMOSOME DELETION; DNA, NEOPLASM; DNA-BINDING PROTEINS; GENE DELETION; HELIX-LOOP-HELIX MOTIFS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MUTATION; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS;

EID: 0031799849     PISSN: 10452257     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2264(199808)22:4<295::AID-GCC5>3.0.CO;2-Q     Document Type: Article

References (45)

1. Atkin NB, Baker MC (1985) Chromosome study of five cancers of the prostate. Hum Genet 70:359-364.
2. Aver DE, Kretzner L, Eiseman RN (1993) MAD: A heterodimeric partner for MAX that antagonizes MYC transcripcionul activity. Cell 72:211-222.
3. Bergerheim USR, Kunimi K, Collins VP, Ekman P (1991) Deletion mapping of chromosomes 8, 10, and 16 in human prostatic carcinoma. Genes Chromosomes Cancer 3:215-220.
4. Blackwood EM, Eisenman RN (1991) Max: A helix-loop-helix- zipper protein that forms a sequence-specific DNA binding complex with MYC. Science 251:1211-1217.
5. Brothman AR (1997) Cytogenetic studies in prostate cancer: Are we making progress? Cancer Genet Cytogenet 95:116-121.
6. Brothman AR, Williams BJ (1997) Prostate Cancer. In Wolman SR, Sell S (eds): Cytogenetic Markers. Totowa: Human Press Inc., pp 223-246.
7. Brothman AR, Peehl DM, Patel AM, McNeal JE (1990) frequency and pattern of karyotypic abnormalities in human prostate cancer. Cancer Res 50:3795-3803.
8. Cher ML, Bova GS, Moore DH, Small EJ, Carroll PR, Pin SS, Epstein JI, Isaacs WB, Jensun RH (1996) Genetic alterations in untreated metastases and androgen-independent prostate cancer detected by comparative genomic hybridization and allelotyping. Cancer Res 56:3091-3102.
9. Cultrano CM, Bino T, Segal S (1997) Function of the MYC antagonist Mad1 during a molecular switch from proliferation to differentiation. Mol Cell Biol 17:2353-2359.
10. Davis LJ, Halazonetis TD (1992) Both the helix-loop-helix and the leucine zipper motifs of MYC contribute to its dimerization specificity with MAX. Oncogene 8:125-132.
11. Deubler DA, Williams BJ, Zhu XL, Steele MR, Rohr LR, Jensen JC, Stephenson RA, Changus JE, Miller GJ, Becich MJ, Brothman AR (1997) Allelic loss detected on chromosomes 8, 10, and 17 by fluorescence in situ hybridization using single-copy P1 probes on isolated nuclei from paraffin-embedded prostate tumors. Am J Path 150:841-850.
12. Eagle LR, Yin X, Brothman AR, Williams BJ, Atkin NB, Prochownik EV (1995) Mutation of the MXI1 gene in prostate cancer. Nature Genetics 9:249-255.
13. Edclhoff S, Ayer DE, Zervos AS, Steingrimsson E, Jenkins NA, Copeland NG, Eisenman RN, Brent R, Disteche CM (1994) Mapping of two genes encoding members of a distinct subfamily of MAX interacting proteins: MAD to human chromosome 2 and mouse chromosome 6, and MXI1 to human chromosome 10 and mouse chromosome 19. Oncogene 9:665-668.
14. Epstein I (1989) Prostate Biopsy Interpretations, Biopsy Interpretation Series. New York: Raven Press, Inc.
15. Evan GI, Littlewood TD (1993) The role of MYC in growth. Curr Opin Genet Dev 3:44-49.
16. Ferre-D'Amare AR, Prendergast GC, Ziff EB, Burley SK (1993) Recognition by MAX of its cognate DNA through a chimeric b/HLH/Z domain. Nature 363:38-45.
17. Garcia-Marco JA, Price CM, Catovsky D (1997) Interphase cytogenetics in chronic lymphocytic leukemia. Cancer Genet Cytogenet 94:52-58.
18. Gray IC, Phillips SM, Lee SJ, Neoptolemos JP, Weissenback J, Spurr NK (1995) Loss of chromosomal region 10q23-q25 in prostate cancer. Cancer Res 55:4800-1803.
19. Gupta K, Anand G, Yin XY, Prochownik EV (1998) Mmipl: A novel leucine zipper protein that reverses the suppressive effects of MAD family members on MYC. Oncogene 16:1149-1159.
20. Hurlin PJ, Queva C, Koskinen PJ, Steingrimsson E, Aver DE, Copeland NG, Jenkins NA, Eisenman RN (1995) MAD3 and MAD4: Novel MAX-interacting transcriptional repressors that suppress MYC-dependent transformation and are expressed during neural and epidermal differentiation. EMBO J 14:5646-5659.
21. Ichikawa T, Nihei N, Kuramochi H, Kawana Y, Killary AM, Rinker-Schaeffer CW, Barrett JC, Isaacs JT, Kugoh H, Oshimura M, Shimazaki J (1996) Metastatic suppressor genes for prostate cancer. Prostate. 6(Suppl):31-35.
22. Ittman M (1996) Allelic loss on chromosome 10 in prostate adenocarcinoma. Cancer Res 56:2143-2147.
23. Jenkins RB, Qian J, Lieber MM, Bostwick DG (1997) Detection of MYC oncogene amplification and chromosomal anomalies in metastatic prostate carcinoma by fluorescence in situ hybridization. Cancer Res 57:524-531.
24. Jones E, Zhu XL, Rohr LR, Stephenson RA, Brothman AR (1994) Aneusorny of chromosomes 7 and 17 detected by FISH in prostate cancer and the effects of selection in vitro. Genes Chromosomes Cancer 11:163-170.
25. Kato GJ, Lee WMF, Chen L, Dang CV (1992) MAX: Functional domains and interactions with C-Myc. Genes Dcvel 6:81-92.
26. Kawamata N, Park D, Wilczynski S, Yokata J, Koefler HP (1996) Point mutations of the MXI1 gene are rare in prostate cancers. Prostate 29:191-193.
27. Keohavong P, Zhu D, Whiteside TL, Swalsky P, Bakker A, Elder EM, Siegfried JM, Srivastava S, Finkelstein SD (1997) Detection of infrequent and multiple K-ras mutations in human tumors and tumor-adjacent tissues. Anal Biochem 247:394-403.
28. Koskinen PJ, Alitalo K (1993) Role of myc amplification and overexprcssion in cell growth, differentiation and death. Sem Cancer Biol 4:3-12.
29. Lacombe L, Orlow I, Renter VE, Fair WR, Dalbagni G, Zhang ZF, Condon-Cardo D (1996) Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer. Int J Cancer 69:110-113.
30. Li J, Yen C, Liaw D, Posypanina K, Bose S, Wang SJ, Pue SJ, Miliaresis C, Rodgers I, MeCombie R, Bigner SH, Giovanella BC, Ittman M, Tyeko B, Hibshoosh H, Wigler MH, Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275:1943-1947.
31. Lundgren R, Kristoffersson U, Heim S, Mandahl N, Mitelman F (1988) Multiple structural chromosome rearrangements, including del(7q) and del(10)q), in an adenocarcinoma of the prostate. Cancer Genet Cytogenet 35:103-108.
32. Marshall R, Shtalgrid M, Talpaz M, Kantarjian H, Smith L, Beran M, Cork A, Trujillo J, Gutterman J, Deisseroth A (1990) Rearrangement and expression of p53 in the chronic phase and blast crisis of chronic myelogenous leukemia. Blood 75:180-189.
33. Nakai H, Misawa S, Toguchida J, Yandell DW, Ishizaki K (1992) Frequent p53 gene mutations in blast crisis of chronic myelogenous leukemia, especially in mycloid crisis harboring loss of chromosome 17p. Cancer Res 52:6588-6593.
34. Packham G, Cleveland JL (1995) MYC and apoptosis. Biochim Biophys Acta 1242:11-28.
35. Prendergast GC, Lowe D, Ziff EB (1991) Association of myn, the murine homolog of MAX, with c-Myc stimulates methylation- sensitive DNA binding and Ras cotransformation. Cell 65:395-407.
36. Prochownik EV, VanAntwerp ME (1992) Differential patterns of DNA binding by Myc and Max proteins. Proc Natl Acad Sci USA 90:960-964.
37. Roussel MF, Ashmun RA, Sherr CJ, Eisenman RN, Ayer DE (1996) Inhibition of cell proliferation by the Mad1 transcriptional represser. Mol Cell Biol 16:2796-2801.
38. Shapiro DN, Valentine V, Kagle L, Yin X, Morris SW, Prochownik EV (1994) Assignment of the human MAD and MXI1 genes to chromosomes 2p12-13 and 10q24-25. Genomics 23:282-285.
39. Sidransky D, Mikkelson T, Schwechheimer K, Rosenblum ML, Cavanee W, Vogelstein B (1992) Clonal expansion of p53 mutant cells in association with brain tumor progression. Nature 355:846-847.
40. Stone J, DeLange T, Ramsay G, Jakobovits E, Bishop JM, Varmus H, Lee W (1987) Definition of regions of human e-MYC that are involved in transformation and nuclear localisation. Mol Cell Biol 7:1697-1709.
41. Trybus TM, Burgess AC, Wojno KJ, Glover TW, Macoska JA (1996) Distinct areas of allelic loss on chromosomal regions 10p and 10q in human prostate cancer. Cancer Res 56:2263-2267.
42. Wechsler DS, Hawkins Al, Li X, Jabs EQ, Griffin CA, Dang CV (1994) Localization of the human MXI1 transcription factor gene to chromosome 10q24-25. Genomics 21:668-672.
43. Wechsler DS, Shelly CA, Petroff CA, Dand CV (1997) MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res 57:4905-4912.
44. Williams BJ, Jones E, Zhu XL, Steele MR, Stephenson RA, Rohr LR, Brothman AR (1996) Evidence for a tumor suppressor gene distal to BRCA1 in prostate cancer. J Urol 155:720-725.
45. Zervos A, Gyuris J, Brent R (1993) MXI1, a protein that specifically interacts with MAX to hind myc-MAX recognition sites. Cell 72:223-232.